Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 8:2019:5952742.
doi: 10.1155/2019/5952742. eCollection 2019.

The Effects of Safflower Yellow on Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Clinical Trial

Xiao-Jin Li  1   2   3 , Yan Kang  1 , Ru-Rong Wang  4 , Xue-Lian Liao  1 , Xiao-Feng Ou  1 , Jin Liu  4 , Yun-Xia Zuo  4
Affiliations

The Effects of Safflower Yellow on Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Clinical Trial

Xiao-Jin Li et al. Evid Based Complement Alternat Med. .

Abstract

Objectives: To evaluate the efficacy of safflower yellow in the acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

Methods: In a prospective, randomized, controlled trial, 127 patients who met the inclusion criteria were enrolled and were randomly divided into two groups. The control group included 64 patients treated according to the global strategy for diagnosis, management, and prevention of COPD (www.goldcopd.org, updated 2011). The intervention group included 63 patients who received intravenous infusions of safflower yellow (100 mg of safflower yellow dissolved in 250 ml 0.9% saline) once daily for 14 consecutive days in addition to standard diagnosis and treatment. The difference in the average length of the hospital stay between the two groups of patients was determined. The follow-up period was 28 days; the differences in symptoms, clinical indicators, and 28-day mortality in the two groups were compared. Statistical analysis was conducted using SPSS 22.0 software to determine whether there were statistically significant differences (P <0.05) between groups.

Results: There were no statistically significant differences between the intervention group and the control group in changes in secondary indicators. There were no statistically significant differences in the 28-day mortality or in the survival curves of the two groups (P=0.496 and P=0.075, respectively). Safflower yellow treatment of AECOPD may relieve the patient's clinical symptoms, such as dyspnoea, shorten the average length of hospital stay (P=0.006, respectively), and decrease the duration of mechanical ventilation.

Conclusion: Safflower yellow in the treatment of AECOPD has a degree of clinical value. This trial is registered under the identifier ChiCTR-IPR-17014176.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The molecular structure of hydroxysafflor yellow A.
Figure 2
Figure 2
Therapy protocol for all patients.
Figure 3
Figure 3
Patient flow diagram.
Figure 4
Figure 4
Kaplan-Meier survival curves of the intervention and control groups (P=0.075, all causes). Group 1: control group (blue line); Group 2: intervention group (green line).
See this image and copyright information in PMC

References

    1. Antó J. M., Vermeire P., Vestbo J., Sunyer J. Epidemiology of chronic obstructive pulmonary disease. European Respiratory Journal. 2001;17(5):982–994. doi: 10.1183/09031936.01.17509820. - DOI - PubMed
    1. Vogelmeier C. F., Criner G. J., Martinez F. J., et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. American Journal of Respiratory and Critical Care Medicine. 2017;195(5):557–582. doi: 10.1164/rccm.201701-0218PP. - DOI - PubMed
    1. Wilt T. J., Niewoehner D., MacDonald R., Kane R. L. Management of stable chronic obstructive pulmonary disease: A systematic review for a clinical practice guideline. Annals of Internal Medicine. 2007;147(9):639–653. doi: 10.7326/0003-4819-147-9-200711060-00009. - DOI - PubMed
    1. Qaseem A., Wilt T. J., Weinberger S. E., et al. Disease: a clinical practice guideline update from the american college of physicians, american college of chest physicians, american thoracic society, and european respiratory society. Annals of Internal Medicine. 2011;155(3):179–191. doi: 10.7326/0003-4819-155-3-201108020-00008. - DOI - PubMed
    1. Buist A. S., McBurnie M. A., Vollmer W. M., et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. The Lancet. 2007;370(9589):741–750. doi: 10.1016/s0140-6736(07)61377-4. - DOI - PubMed

LinkOut - more resources